




# Intensified upstream operations

With Xcellerex™ Automated  
Perfusion System (APS)

Radhika Jayakar  
June, 2022



# Agenda

1. Introduction
2. Case study: N-1 perfusion for fed-batch processes
3. Bring consistency to perfusion: introducing Xcellerex™ APS
4. Summary

# 1

## Introduction

# Market trends and business drivers adapted from BPOG Technology roadmap

## Market trends

### Market growth

High demand  
Number of drugs supplied  
Global reach and emerging markets

### New product classes

New treatment modalities  
Personalized medicine

### Uncertainty

Clinical efficacy, dose requirements  
Product approvals, complex regulations  
Demand, competition, and market share  
Regional/political requirements

### Cost pressure

Payer pressure on price  
Biosimilars and competition  
Cost of clinical failure  
Escalating development costs

## Business drivers

### Facility flexibility

Facility design and scale  
Multiproduct capability  
Regional manufacture

### Speed

Speed to clinic  
Speed to build  
Speed to market  
Speed to supply

### Quality

Product attributes and characterization  
Comparability requirements  
Quality/risk management  
Cost of nonquality

### Cost reduction

Development costs  
Facility investments, timing  
Construction and validation costs  
Manufacturing costs

# How are we addressing current and future needs?

**Facility**



**Single-use  
technology**



**Automation,  
process control,  
and digitalization**



**Process  
intensification**



# What is next-generation processing?

## Intensified process



**OPTIMIZED  
TECHNOLOGY**



**SIMPLIFIED  
OPERATIONS**



**DATA  
ANALYTICS**

## Continuous manufacturing

### Process intensification of existing bottlenecks


#### Solutions:

- Perfusion media development
- Intensified seed train
- Intensified production bioreactor
- Intensified capture
- Inline conditioning/dilution
- Inline viral inactivation
- Flow-through polishing
- Inline virus removal
- Single-pass formulation

# 2


## **Case study: N-1 seed perfusion for fed- batch production process**

# Seed train perfusion can reduce time and/or bioreactor size






# Up to 20-fold greater seed scale-up



| N-1 working volume | Seed volume at 0.5 MVC/mL |
|--------------------|---------------------------|
| 5 L                | 50 L                      |
| 25 L               | 250 L                     |
| 50 L               | 500 L                     |



| N-1 working volume | Seed volume at 0.5 MVC/mL |
|--------------------|---------------------------|
| 5 L                | 1000 L                    |
| 25 L               | 5000 L                    |
| 50 L               | 10 000 L                  |


# N-1 perfusion set-up using Xcellerex™ APS and XDR-50

## Objective

- Establish a CSPR based N-1 perfusion process targeting at least 100 MVC/mL in ReadyToProcess WAVE™ 25
- Maintain cells in exponential growth with a cell viability above 95%
- Scale the process to XDR-50 using Xcellerex™ APS
- Compare growth and productivity of production cultures seeded with N-1 perfused cells and with a conventional seed train





# Perfusion N-1 Seed - ReadyToProcess WAVE™ 25 vs APS XDR-50




Effective scale-down of perfusion seed process using ReadyToProcess WAVE™ 25 for process development scale. Representative of perfusion seed performance in Xcellerex™ XDR-50 with APS

# Seed growth to 179 MVC/mL in Xcellerex™ XDR-50 with APS






# Comparable growth and productivity in fed-batch using N-1 inoculum



N-1 perfusion seed (179 MVC/mL) and N-1 batch seed as inoculum for fed-batch production culture

# N-1 perfusion does not affect final product quality attributes



# Conclusion

- Successful N-1 perfusion run in the XDR-50 using the Xcellerex™ APS
- We were able to achieve exponential growth to 179 MVC/mL and a cell viability over 95%.
  - An improvement in terminal seed densities of traditional methods - batch (5 MCV/mL) and rocking bioreactor perfusion methods (50-70 MVC/mL).
  - Processing to higher densities shorten time to production inoculation or allow increase in production process volume.
- ReadyToProcess WAVE™ 25 perfusion process scale in growth profiles with Xcellerex™ APS/XDR-50.
- Resulting production fed-batch process indicate equivalent performance between WAVE™ 25 an Xcellerex™ APS N-1 inoculum.
- Comparison of N-1 perfusion seed trains indicate consistent behavior between product platforms for the growth of both the seed and the subsequent production fed-batch cultures.
- Processing of the final protein of the production fed-batch cultures confirmed consistent protein titers and resulting product quality profiles regardless of seed source.

# 3

## Bring consistency to perfusion

Introducing Xcellerex™ APS




# Automate perfusion and reduce risk while ensuring that your process needs are met

Xcellerex™ APS single-use perfusion system



- Automates upstream process intensification
- Minimizes opportunities for operator errors and lost batches
- Integrates Xcellerex™ bioreactor, automation, sensors, single-use flow kit, hollow fiber filters, and 3D bags
- Intuitive, scalable, single-use perfusion system


# Use the same system for multiple applications in both pilot- and manufacturing-scale GMP operations



# Broad range of operation



# Compact, fully integrated perfusion operation



- **Accurate:** use floor scales to provide gravimetric control
- **Continuous operation:** perfusate can be fed directly to the protein A step

# Simplifying perfusion operations



Intelligent filter switch



Automated liquid management



Connection between Xcellerex™ APS and bioreactor



Single-use flow path installation



Single user interface



Multiple perfusion modes



Automated cell bleed



Cell harvest

# Process simplicity using Xcellerex™ APS Flow kit



- **Rapid start-up:** flow kit sections assembled in less than 15 minutes
- **Simplicity:** back-up filter can be added in seconds and at **any** stage during the cell culture run
- **Minimized bioburden:** closed loop, presterilized, single-use flow path
- **Complete process monitoring:** precalibrated feed, retentate, and permeate pressure flow, as well as two flow sensors
- **Minimized shear on cells:** through smart design that avoids sharp bends in the flow path

# Say goodbye to filter blockage interruptions



- **Unattended operation:** automated back-up filter switching
- **No need for a second system:** back-up filter to prolong process duration
  - Early prediction of filter fouling with key process parameters
  - Series of noncontact pinch valves to direct flow



# Automated perfusion control and process monitoring



- **Maintained steady-state** throughout the process thanks to integrated floor scales (cell bleed, bolus feed addition, evaporation, etc.)
- **Predictable and reliable processing** through a weight-based approach that ensures a very tight process control
- **Extended filter life** through flexible permeate control

|   |                                   |      |
|---|-----------------------------------|------|
| <input checked="" type="checkbox"/> Flexible Permeate Control |                                   |      |
| High Permeate SP  | <input type="text" value="1.10"/> |      |
| Low Permeate SP   | <input type="text" value="0.00"/> | mlpm |
| <input type="button" value="OK"/>                             |                                   |      |



# Low shear operation to maintain cell culture performance



- Utilizes the Levitronix™ single-use maglev centrifugal pump
- Proven performance in perfusion applications
- Handles high-viscosity solutions – ideal for high cell density applications
- Flow path designed to create minimal turbulence

For details see:

Wang S, Godfrey S, Ravikrishnan J, Lin H, Vogel J, Coffman J. Shear contributions to cell culture performance and product recovery in ATF and TFF perfusion systems. *J. Biotechnol.* 2017;246:52-60. <http://dx.doi.org/10.1016/j.jbiotec.2017.01.020>

# Key automation features for enhancing process control and cell growth

## Automated medium bin switching

- Continuous, unattended cell culture medium addition into the bioreactor bag
- Automatically switch to new bin thanks to weight trigger




## Automated cell bleed

- Maintain constant bioreactor cell density through automated cell bleed
- Cells can be bled from the bioreactor continuously or in bolus, enabling control of the cell density and cell growth



# Fully integrated automation as standard



- Seamless integration with Xcellerex™ XDR bioreactors
- Simplified reporting: combined batch record for bioreactor and perfusion system
- Full monitoring and control with an interactive process layout

# 4

## Summary

# Bring consistency and flexibility to perfusion



- **Versatile**  
Flexible choice of hollow fiber filters, bioreactor sizes, accessories, and control options for efficiency.
- **Efficient**  
One automation platform and single user interface for Xcellerex™ bioreactors and Xcellerex™ APS supports traceability.
- **Productive**  
Easy filter change-over, liquid management switch, and cell bleed enhance process control and accuracy. This supports maintaining high cell densities with high cell viability, which boost productivity.



# Designed for high cell density needs



- Bioreactor sizes up to 500 L
- Recirculation flow rate of 18 L/min max
- Hollow fiber cartridges micro/ultra, up to 4.4 m<sup>2</sup>
- VVD of 0.075 to 2.0
- CSPR of 20 to 50 pL/cells/d

CSPR = cell specific perfusion rate  
VVD = volume of fresh medium/working volume of reactor/day

## Call to action

*Do you want to see what APS can do for your process?*

- Schedule a demo
- Visit Cytiva website for more information on [Xcellerex APS](#)
- Read the [intensified seed culture for a fed-batch process Application Note](#)
- Contact your [Cytiva representative](#) for more information

# Thank you

**Radhika Jayakar**

radhika.jayakar@cytiva.com





Cytiva and the Drop logo are trademarks of Global Life Sciences IP Holdco LLC or an affiliate. ActiPro, Cell Boost, Figurate, HiTrap, HyClone, ReadyMate, ReadyToProcess, ReadyToProcess WAVE, and Xcellerex are trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.

The Xcellerex APS (Automated Perfusion System) system is designed for perfusion cell culturing and may therefore be used for a broad variety of cell culture processes (e.g. in the field of intensified and/or continuous cell culturing). Purchaser shall at all times be solely responsible for obtaining any additional intellectual property rights necessary for the use of the Xcellerex APS system for their specific cell culture processes.

ReadyMate: this product is covered by US patent number 6,679,529 B2 owned by Johnson & Boley Holdings, LLC and licensed to Cytiva.

Levitronix is a trademark of Levitronix GmbH. Microsoft and Windows are registered trademarks of Microsoft Corporation. All other third-party trademarks are the property of their respective owners.

© 2020 Cytiva

All goods and services are sold subject to the terms and conditions of sale of the supplying company operating within the Cytiva business. A copy of those terms and conditions is available on request. Contact your local Cytiva representative for the most current information.

For local office contact information, visit [cytiva.com/contact](https://www.cytiva.com/contact)